Gender differences in retention and survival on antiretroviral therapy of HIV-1 infected adults in Malawi

Malawi Medical Journal

Volumn 22, Issue 2, 2010, Pages 49-56

  Taylor Smith, Katie ^a   Tweya, Hannock ^b   Harries, Anthony ^c   Schoutene, Erik ^d   Jahn, Andreas ^d  

^a MÉDECINS SANS FRONTIÈRES   (Belgium)

^b KAMUZU CENTRAL HOSPITAL   (Malawi)

^c INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^d MINISTRY OF HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957068923     PISSN: 19957262     EISSN: 19957270     Source Type: Journal    
DOI: 10.4314/mmj.v22i2.58794     Document Type: Article

References (36)

1. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. Jama 1998; 280: 1497-1503.
2. CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000: 355: 1158-1159.
3. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002; 360: 34-40.
4. Wester C W, Kim S, Bussmann H, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defc Syndr 2005; 40: 336-343.
5. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. Aids 2004; 18: 887-895.
6. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. Jama 2006: 296: 782- 793.
7. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006; 43: 770-776.
8. Jahn A, Floyd S, Crampin AC, et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 2008; 371: 1603-1611.
9. Perez-Hoyos S, del Amo J, Muga R, et al. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. Aids 2003; 17: 353-359.
10. Hall HI, McDavid K, Ling Q, Sloggett A. Determinants of progression to AIDS or death after HIV diagnosis, United States, 1996 to 2001. Ann Epidemiol 2006; 16: 824-833.
11. Moore AL, Kirk O, Johnson AM, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defc Syndr 2003; 32: 452-461.
12. d'Arminio A, Sabin CA, Phillips AN, et al. (2004) Cardio and cerebrovascular events in HIV-infected persons. Aids 2004; 18: 1811-1817.
13. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L. Generic fxed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. Aids 2006; 20: 1163-1169.
14. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006; 367: 1335-1342.
15. Chen SC, Yu JK, Harries AD, et al. Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi. Trop Med Int Health 2008; 13: 513-519.
16. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. Aids 2006; 20: 1181-1189.
17. Makombe SD, Jahn A, Tweya H, et al. A national survey of the impact of rapid scale-up of antiretroviral therapy on health-care workers in Malawi: effects on human resources and survival. Bull World Health Organ 2007; 85: 851-857.
18. Makombe SD, Jahn A, Tweya H, et al. A national survey of teachers on antiretroviral therapy in Malawi: access, retention in therapy and survival. PLoS ONE 2007; 2: e620.
19. Banda AC, Makombe SD, Jahn A, et al. Antiretroviral therapy in the Malawi defence force: access, treatment outcomes and impact on mortality. PLoS ONE 2008; 3: e1445.
20. Makombe S, Jahn A, Tweya H, et al. The impact of national antiretroviral treatment programme on public services in Malawi: access and survival on therapy among the police force. Malawi Medical Journal 2008; 20: 23-27.
21. World Health Organization. WHO Statistical Information System 2008; http://www.who.int/countries/mwi/en/.
22. National AIDS Commission. HIV and syphilis sero-survey and national HIV prevalence and AIDS estimates. 2007. Lilongwe: Malawi Ministry of Health.
23. Libamba E, Makombe S, Harries AD, et al. Scaling up antiretroviral therapy in Africa: learning from tuberculosis control programmes - the case of Malawi. Int J Tuberc Lung Dis 2005; 9: 1062-1071.
24. Malawi Ministry of Health. Antiretroviral therapy in the public and private sectors in Malawi: results up to 30th September, 2008. Lilongwe: HIV Unit. 2008.
25. Malawi Ministry of Health. Treatment of AIDS: Guidelines for the use of antiretroviral therapy in Malawi. Second Edition. Lilongwe: HIV Unit. Second Edition. 2006.
26. Libamba E, Makombe S, Mhango E, et al. Supervision, monitoring and evaluation of nationwide scale-up of antiretroviral therapy in Malawi. Bull World Health Organ 2006; 84: 320-326.
27. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. Aids 2005; 19: 2141-2148.
28. Zachariah R, Fitzgerald M, Massaquoi M, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. Aids 2006; 20: 2355-2360.
29. Braitstein P, Brinkhof M W, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and highincomecountries. Lancet 2006; 367: 817-824.
30. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. Aids 2003; 17: 2159-2168.
31. Cressey TR, Lallemant M. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. Infect Genet Evol 2007; 7: 333-342.
32. Umeh OC, Currier JS. Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. Expert Opin Drug Metab Toxicol 2006; 2: 273-283.
33. Marshall MM, McCormack MC, Kirk GD. Effect of cigarette smoking on HIV acquisition, progression, and mortality. AIDS Education and Prevention 2009; 21: 28-39
34. Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defc Syndr 2009; August 7. (epub ahead of print)
35. Miguez-Burbano MJ, Lewis JE, Fishman J, Asthana D, Malow RM. The infuence of different types of alcoholic beverages on disrupting highly active antiretroviral treatment (HAART) outcome. Alcohol 2009; 44: 366- 371.
36. Malawi Ministry of Health. ART in the public and private sectors in Malawi: results up to 31st December, 2007. Lilongwe: HIV Unit.2008.